biosectinvestor, I do agree that The Access Consortium is a very good collaborative program for the MHRA to use to get DCVax-L reviewed and approved in multiple countries. It would give DCVax-L a significantly larger addressable GBM market than just the UK alone.
I am also encouraged by the fact that once the MHRA does approve a new drug by using the Access Consortium, they will also fast-track the NICE (National Institute for Health and Care Excellence) appraisal guidance during the new drug review and approval process. That allows for patients to have access to the new drug, and for it to paid for under the NHS (National Health Service).
Here is an example of a new drug that was approved on 5/18/2922 in the UK using the Access Consortium. Then, about a week later, on 5/25/2022, NICE completed its guidance recommending the use of the new drug.
Market Data 
Markets 
AI
